ClinicalTrials.gg
RecruitingNCT07312045Updated Dec 31, 2025

HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy

An observational study in Periodontal Diseases, Periodontitis and Gingivitis; Chronic, sponsored by Ömer Faruk Okumuş. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Ömer Faruk Okumuş · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
180
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Periodontal Diseases with a site in Turkey — 25 open to participants now, 34 under way, none of them phase 3. Periodontal Diseases · Turkey.

Planned enrollment
20th of 91
180 · median 88
Started
2025
with 24 others
Observational
91 of 160
14 open now
Primary completion
2026-11
later than 22 of 33 live
Registered
108th of 160
by date

Among the 160 studies in Periodontal Diseases with a site in Turkey, this one is the 20th largest by planned enrollment of the 91 observational ones that give a count, is one of 25 that started in 2025, is one of 91 observational ones, reaches primary completion later than 22 of the 33 other live ones, and was the 108th registered.

Periodontal Diseases

871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.

Browse Periodontal Diseases studies →

Open to participants now

25 of the 160 studies in Periodontal Diseases with a site in Turkey are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Periodontal Diseases with a site in Turkey, or all of them as a file.
02

Study summary

This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte / Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and salivary MMP-8 levels in individuals with periodontal health, gingivitis, and stage III/IV periodontitis. The study also evaluates how these biomarkers relate to healing following non-surgical periodontal therapy.

A total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III/IV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit.

The primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.

Read the detailed description

Following baseline assessments, participants in the gingivitis and periodontitis groups will receive standard non-surgical periodontal therapy. Periodontal clinical measurements will be repeated at the 3-month follow-up visit in these groups. In accordance with the existing ethics committee approval and following further feasibility assessment, an additional blood sample will be collected at the 3-month follow-up visit exclusively from participants in the periodontitis group.

03

Conditions studied

  • Periodontal Diseases
  • Periodontitis
  • Gingivitis; Chronic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adult individuals aged 18-65 years presenting to the periodontology clinic for routine examination or periodontal treatment. Participants will be assigned to healthy, gingivitis, or stage III/IV periodontitis groups based on periodontal diagnosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years
  • Ability to provide
  • No systemic diseases or conditions affecting periodontal status
  • For Healthy Group: Probing depth ≤3 mm, no attachment loss, no radiographic bone loss
  • For Gingivitis Group: Gingival inflammation and bleeding on probing without attachment loss or bone loss
  • For Periodontitis Group: Stage III or stage IV periodontitis according to 2018 classification
  • No periodontal treatment within the past 6 months
  • Willingness to attend follow-up visits

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases influencing periodontal inflammation (e.g., diabetes, disorders)
  • Current pregnancy or lactation
  • Use of antibiotics, anti-inflammatory medications, or drugs within the last 3 months
  • Smokers or individuals using tobacco products
  • History of periodontal surgery in the last 6 months
  • Presence of fewer than 20 natural teeth
  • Any condition that may interfere with study participation or data reliability
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Periodontally Healthy Individuals

    Participants with no clinical signs of gingival inflammation, probing depth ≤3 mm, no clinical attachment loss, and no radiographic bone loss. These individuals serve as the healthy control group.

    Procedure: Non-surgical Periodontal Therapy

  • Gingivitis Patients

    Participants with visible signs of gingival inflammation and bleeding on probing, but without clinical attachment loss or radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy.

    Procedure: Non-surgical Periodontal Therapy

  • Stage III/IV Periodontitis Patients

    Participants diagnosed with stage III or stage IV periodontitis, characterized by clinical attachment loss, probing depth ≥5 mm, and radiographic bone loss. These individuals will receive standard non-surgical periodontal therapy and will be re-evaluated at 3 months.

    Procedure: Non-surgical Periodontal Therapy

Interventions

  • ProcedureNon-surgical Periodontal Therapy

    Standard full-mouth supra- and subgingival debridement performed in a single session, followed by oral hygiene instructions.

06

What researchers measure

Primary outcomes

  1. Differences in Baseline HALP Score Between Good and Poor Treatment Responders

    Evaluation of whether baseline HALP score differs between good responders (\>2 mm reduction in probing depth at sites ≥5 mm) and poor responders (≤2 mm reduction) following non-surgical periodontal therapy in periodontitis patients.

    Time frame: Baseline (T0) to 3 months after treatment (T2)

Secondary outcomes

  1. Differences in Baseline NLR Between Good and Poor Responders

    Comparison of baseline neutrophil-to-lymphocyte ratio between good and poor responders in the periodontitis group.

    Time frame: Baseline (T0)

  2. Differences in Baseline PLR Between Good and Poor Responders

    Comparison of baseline platelet-to-lymphocyte ratio between good and poor responders in the periodontitis group.

    Time frame: Baseline (T0)

  3. Differences in Baseline LMR Between Good and Poor Responders

    Comparison of baseline lymphocyte-to-monocyte ratio between good and poor responders in the periodontitis group.

    Time frame: Baseline (T0)

  4. Differences in Baseline SII Between Good and Poor Responders

    Comparison of baseline systemic immune-inflammation index between good and poor responders in the periodontitis group.

    Time frame: Baseline (T0)

  5. Differences in Baseline Salivary MMP-8 Between Good and Poor Responders

    Comparison of baseline salivary MMP-8 levels between good and poor responders in the periodontitis group.

    Time frame: Baseline (T0)

  6. Baseline HALP Score Differences Across Periodontal Status Groups

    Comparison of HALP score among healthy, gingivitis, and stage III/IV periodontitis groups.

    Time frame: Baseline (T0)

  7. Baseline NLR Differences Across Periodontal Status Groups

    Comparison of neutrophil-to-lymphocyte ratio among the three periodontal groups.

    Time frame: Baseline (T0)

  8. Baseline PLR Differences Across Periodontal Status Groups

    Comparison of platelet-to-lymphocyte ratio among the three periodontal groups.

    Time frame: Baseline (T0)

  9. Baseline LMR Differences Across Periodontal Status Groups

    Comparison of lymphocyte-to-monocyte ratio among the three periodontal groups.

    Time frame: Baseline (T0)

  10. Baseline SII Differences Across Periodontal Status Groups

    Comparison of systemic immune-inflammation index among the three periodontal groups.

    Time frame: Baseline (T0)

  11. Baseline Salivary MMP-8 Differences Across Periodontal Status Groups

    Comparison of salivary MMP-8 among healthy, gingivitis, and periodontitis groups.

    Time frame: Baseline (T0)

  12. Changes in Probing Depth After Non-Surgical Periodontal Therapy

    Mean reduction in probing depth from baseline to 3 months in gingivitis and periodontitis patients.

    Time frame: Baseline (T0) to 3 months (T2)

  13. Change in HALP Score After Non-Surgical Periodontal Therapy in Periodontitis Patients

    Evaluation of the change in HALP score from baseline to 3 months after non-surgical periodontal therapy in patients with stage III/IV periodontitis.

    Time frame: Baseline (T0) to 3 months (T2)

  14. Correlations Between Clinical Periodontal Parameters and Biomarker Levels

    Assessment of correlations between probing depth, bleeding on probing, plaque index, clinical attachment level, and biomarkers including HALP score, NLR, PLR, LMR, SII, and salivary MMP-8.

    Time frame: Baseline (T0)

07

Study locations

1 of 1 sites recruiting
  • Erzincan Binali Yıldırım University Faculty of Dentistry
    Merkez, Erzincan 24002, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

Of 79 non-industry observational studies under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 12 months is close to that.

Counting every sponsor, half of 83 studies reached it within 13 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 31, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Nov 25, 2026
CompletionEst.
Nov 25, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07312045
Lead sponsor
Ömer Faruk Okumuş
Collaborators
Erzincan Binali Yildirim Universitesi
Responsible party
Ömer Faruk Okumuş (Assistant Professor, Erzincan University) — Sponsor-investigator
First posted
Dec 31, 2025
Start date
Nov 25, 2025
Primary completion
Nov 25, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Ömer Faruk Okumuş, Assistant Professor
Contact
okumus.omer24@gmail.com
+905532140969

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion